SARS-CoV-2 Infection
Showing NaN - NaN of 7
SARS-CoV-2 Infection, COVID-19 Trial in United States (BNT162b2 (Omi XBB.1.5))
Not yet recruiting
- SARS-CoV-2 Infection
- COVID-19
- BNT162b2 (Omi XBB.1.5)
-
Dublin, California
- +14 more
Aug 10, 2023
SARS-CoV-2 Infection, COVID-19 Trial in United States (BNT162b2)
Completed
- SARS-CoV-2 Infection
- COVID-19
- BNT162b2
-
Anaheim, California
- +20 more
Nov 30, 2022
SARS-CoV-2 Infection, COVID-19 Trial in Worldwide (BNT162b2, Placebo, BNT162b2 OMI)
Recruiting
- SARS-CoV-2 Infection
- COVID-19
- BNT162b2
- +4 more
-
Athens, Alabama
- +158 more
Jul 18, 2022
SARS-CoV-2 Infection Trial in United States (Evusheld (tixagevimab+cilgavimab) IM or IV)
Recruiting
- SARS-CoV-2 Infection
- Evusheld (tixagevimab+cilgavimab) IM or IV
-
Fountain Valley, California
- +33 more
Jun 24, 2022
COVID on Children and Families
Recruiting
- SARS-CoV-2 Infection
-
Birmingham, Alabama
- +64 more
May 5, 2022
SARS-CoV-2 Infection Trial in Worldwide (Intramuscular injection, Intramuscular vaccine)
Active, not recruiting
- SARS-CoV-2 Infection
- Intramuscular injection
- Intramuscular vaccine
-
Birmingham, Alabama
- +90 more
Apr 4, 2022
Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection Trial in United States (20-valent pneumococcal conjugate vaccine (20vPnC),
Completed
- Pneumococcal Disease
- +2 more
- 20-valent pneumococcal conjugate vaccine (20vPnC)
- +2 more
-
Anaheim, California
- +28 more
Mar 23, 2022